Evofem Biosciences (EVFM) Competitors $0.01 +0.00 (+10.99%) As of 03:20 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EVFM vs. SNOA, PBM, QLGN, NLSP, CPHI, ONCO, KTTA, RDHL, APVO, and INMShould you be buying Evofem Biosciences stock or one of its competitors? The main competitors of Evofem Biosciences include Sonoma Pharmaceuticals (SNOA), Psyence Biomedical (PBM), Qualigen Therapeutics (QLGN), NLS Pharmaceutics (NLSP), China Pharma (CPHI), Onconetix (ONCO), Pasithea Therapeutics (KTTA), Redhill Biopharma (RDHL), Aptevo Therapeutics (APVO), and InMed Pharmaceuticals (INM). These companies are all part of the "pharmaceutical products" industry. Evofem Biosciences vs. Its Competitors Sonoma Pharmaceuticals Psyence Biomedical Qualigen Therapeutics NLS Pharmaceutics China Pharma Onconetix Pasithea Therapeutics Redhill Biopharma Aptevo Therapeutics InMed Pharmaceuticals Sonoma Pharmaceuticals (NASDAQ:SNOA) and Evofem Biosciences (NASDAQ:EVFM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, dividends, risk and institutional ownership. Is SNOA or EVFM more profitable? Sonoma Pharmaceuticals has a net margin of -23.87% compared to Evofem Biosciences' net margin of -46.42%. Sonoma Pharmaceuticals' return on equity of -50.00% beat Evofem Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Sonoma Pharmaceuticals-23.87% -50.00% -16.79% Evofem Biosciences -46.42%-91.97%-61.93% Does the media favor SNOA or EVFM? In the previous week, Evofem Biosciences had 1 more articles in the media than Sonoma Pharmaceuticals. MarketBeat recorded 2 mentions for Evofem Biosciences and 1 mentions for Sonoma Pharmaceuticals. Sonoma Pharmaceuticals' average media sentiment score of 0.67 beat Evofem Biosciences' score of 0.60 indicating that Sonoma Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sonoma Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evofem Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in SNOA or EVFM? 2.0% of Sonoma Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Evofem Biosciences shares are held by institutional investors. 24.6% of Sonoma Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Evofem Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has higher valuation and earnings, SNOA or EVFM? Evofem Biosciences has lower revenue, but higher earnings than Sonoma Pharmaceuticals. Sonoma Pharmaceuticals is trading at a lower price-to-earnings ratio than Evofem Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSonoma Pharmaceuticals$14.29M0.42-$3.46M-$2.46-1.50Evofem Biosciences$11.39M0.11$52.98M-$0.07-0.14 Which has more risk & volatility, SNOA or EVFM? Sonoma Pharmaceuticals has a beta of 1.46, indicating that its share price is 46% more volatile than the S&P 500. Comparatively, Evofem Biosciences has a beta of -1.13, indicating that its share price is 213% less volatile than the S&P 500. Do analysts rate SNOA or EVFM? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sonoma Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Evofem Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummarySonoma Pharmaceuticals beats Evofem Biosciences on 10 of the 14 factors compared between the two stocks. Get Evofem Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for EVFM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding EVFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EVFM vs. The Competition Export to ExcelMetricEvofem BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.28M$1.01B$6.17B$10.67BDividend YieldN/A4.84%5.72%4.86%P/E Ratio-0.021.2529.6628.52Price / Sales0.1129.59578.54129.10Price / CashN/A17.6337.1261.42Price / Book0.007.6912.046.52Net Income$52.98M-$7.91M$3.32B$276.75M7 Day PerformanceN/A-1.56%-0.16%0.20%1 Month PerformanceN/A23.49%5.76%1.67%1 Year PerformanceN/A-14.91%65.71%32.73% Evofem Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EVFMEvofem Biosciences1.4878 of 5 stars$0.01+11.0%N/A-9.0%$1.28M$11.39M-0.02120SNOASonoma Pharmaceuticals1.3222 of 5 stars$4.00-1.7%N/A+29.1%$6.56M$14.29M-1.63180PBMPsyence Biomedical0.4292 of 5 stars$3.45-3.2%N/A-95.0%$6.44MN/A0.00N/AShort Interest ↑Gap DownQLGNQualigen TherapeuticsN/A$3.77-6.0%N/A-62.1%$6.41M$4.98M0.0050Negative NewsNLSPNLS PharmaceuticsN/A$1.75-1.1%N/A-67.1%$6.30MN/A0.006News CoverageGap DownCPHIChina Pharma0.2377 of 5 stars$1.86-0.1%N/A-93.1%$6.06M$4.40M0.00250Short Interest ↑ONCOOnconetix0.2398 of 5 stars$3.65-1.0%N/A-99.2%$5.65M$2.52M0.0012Short Interest ↑KTTAPasithea Therapeutics1.0428 of 5 stars$0.75+0.2%N/A-83.0%$5.55MN/A-0.103Positive NewsRDHLRedhill BiopharmaN/A$1.62-0.6%N/A-79.1%$5.43M$8.04M0.00210News CoverageGap DownAPVOAptevo Therapeutics0.2773 of 5 stars$1.63+1.6%N/A-100.0%$5.35M$3.11M0.0050Gap DownINMInMed Pharmaceuticals0.4639 of 5 stars$2.18+2.4%N/A-67.7%$5.24M$4.94M-0.1810Short Interest ↑ Related Companies and Tools Related Companies Sonoma Pharmaceuticals Alternatives Psyence Biomedical Alternatives Qualigen Therapeutics Alternatives NLS Pharmaceutics Alternatives China Pharma Alternatives Onconetix Alternatives Pasithea Therapeutics Alternatives Redhill Biopharma Alternatives Aptevo Therapeutics Alternatives InMed Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EVFM) was last updated on 10/23/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evofem Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evofem Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
